Qing-Dai for pediatric ulcerative colitis multicenter survey and systematic review

Area of Science:

• Gastroenterology
• Pediatric Gastroenterology
• Pharmacology

Background:

• Pediatric ulcerative colitis (UC) presents unique treatment challenges compared to adult cases.
• Qing-Dai, a treatment effective in adults, lacks reported efficacy data in pediatric UC.
• This study investigates the use of Qing-Dai in pediatric UC patients in Japan.

Purpose of the Study:

• To determine the efficacy of Qing-Dai therapy in pediatric patients with ulcerative colitis.
• To assess the safety and adverse events associated with Qing-Dai use in this population.
• To provide data on short-term and long-term outcomes of Qing-Dai treatment for pediatric UC.

Main Methods:

• A questionnaire survey was distributed to 31 high-volume pediatric inflammatory bowel disease centers in Japan.
• Data collected included patient numbers, treatment initiation, short-term and long-term effects, and adverse events.
• A systematic review of existing literature on Qing-Dai efficacy and safety for UC was also conducted.

Main Results:

• Qing-Dai was used by 107 pediatric UC patients, with 78.5% initiating treatment.
• Within six months, 80.2% achieved clinical remission, and 64.1% experienced no relapse.
• Adverse events included one case of pulmonary arterial hypertension (PAH) among patients with regular follow-ups; the systematic review found a 1.2% PAH incidence.

Conclusions:

• Qing-Dai demonstrates significant efficacy in treating pediatric ulcerative colitis.
• The therapy is associated with a risk of adverse events, notably pulmonary arterial hypertension (PAH).
• Qing-Dai should be used cautiously in pediatric UC patients, with careful monitoring for side effects.